金十数据6月9日讯，常山药业6月9日公告，股票连续两个交易日收盘价格涨幅偏离值累计超过30%，根 据深圳证券交易所的相关规定，属于股票交易异常波动的情况。自2025年5月6日至6月9日期间，公司股 价累计涨幅达147.69%，已经严重偏离同行业和创业板综合指数增长幅度。公司艾本那肽注射液用于治 疗2型糖尿病的上市许可申请已经获得国家药监局受理，目前处于专业审评阶段，艾本那肽注射液上市 审评后续环节仍然较多，艾本那肽最终能否获批上市及获批时间仍存在不确定性。公司艾本那肽注射液 拟用于减重适应症的临床试验申请已经获得国家药监局受理，目前处于审评阶段，能否获得临床试验批 准通知书存在不确定性。 常山药业：艾本那肽注射液处于审评阶段，能否获批存在不确定性 ...

Core Viewpoint - Changshan Pharmaceutical's application for the marketing authorization of Abemaciclib injection for type 2 diabetes has been accepted, but there is uncertainty regarding its approval and timeline [1] Group 1: Stock Performance - The company's stock price has deviated significantly, with a cumulative increase of 147.69% from May 6 to June 9, which is over 30% deviation from the industry and ChiNext index growth [1] Group 2: Product Development - The application for clinical trials of Abemaciclib injection for weight loss indications has also been accepted, but there is uncertainty about receiving the approval notice [1]

证券代码：300255 证券简称：常山药业 公告编号：2025-28 河北常山生化药业股份有限公司 4．公司 2024 年度营业收入为 103,081.05 万元，较上年下降 26.92%；归属于上 市公司股东的净利润为亏损 24,947.77 万元；基本每股收益为亏损 0.27 元/股。具体 情况详见公司 2025 年 4 月 29 日于巨潮资讯网站发布的《2024 年年度报告》（公告编 号 2025-11），并请关注其中详述公司经营所面临的风险。 股票交易异常波动公告 本公司及其董事会全体成员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏。 特别提示： 1．河北常山生化药业股份有限公司（以下简称"公司"）股票连续两个交易日 （2025 年 6 月 6 日、2025 年 6 月 9 日）收盘价格涨幅偏离值累计超过 30%，根据深 圳证券交易所相关规定，属于股票交易异常波动的情况。自 2025 年 5 月 6 日至 6 月 9 日期间，公司股价累计涨幅达 147.69%，已经严重偏离同行业和创业板综合指数增 长幅度，存在市场情绪过热的情形，可能存在非理性交易行为，公司股价可能存在 ...

炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ A股今日强势上扬，沪指盘中突破3400点，创业板指涨超1%；港股亦走强，恒生指数涨超1%重返24000 点上方，恒生科技指数大涨近3%，自4月低点涨幅超过20%，迈入技术性牛市。 行业方面，当地时间2025年5月30日至6月3日，2025年美国临床肿瘤学会（ASCO）年会在美国芝加哥 举行。随着美国临床肿瘤学会（ASCO）年会的召开和落幕，以及今年国内药企屡屡斩获大额全球授权 交易，二级市场反响热烈。 光大证券指出，本次年会见证了中国药企在新药研发方面的活跃度和竞争力，其间多项成果和数据惊艳 亮相，持续看好国产创新药的发展前景，特别是在临床进展和国际化布局方面有优势的企业。此外，5 月7日以来，我国已推出一揽子金融政策支持稳市场稳预期，其中货币政策和财政政策的支持力度均较 大。考虑到降息降准政策，业绩稳健增长、具备高股息特征的龙头药企具备较强的投资吸引力。 稀土板块活跃 具体来看，三大股指盘中震荡走高，沪指一度收复3400点，创业板指、北证50指数涨超1%。截至收 盘，沪指涨0.43%报3399.77点，深证成指涨0.65%报10250 ...

常山药业（300255）今日涨停，成交额35.32亿元，换手率7.75%，盘后龙虎榜数据显示，深股通专用席 位买入2.57亿元并卖出1.52亿元，二机构专用席位净买入1.12亿元，一机构专用席位净卖出4283.52万 元。 暗盘资金一眼洞悉庄家意图>> ...

热点概览： A股三大指数今日高开高走，截至收盘，沪指涨0.43%一度站上3400点，深成指涨0.65%，创业板指涨1.07%，北证50指数涨1.08%。全 市场成交额13126亿元，较上日放量1355亿元。全市场超4100只个股上涨。 板块题材上，创新药、足球概念、可控核聚变、互联网金融板块涨幅居前；贵金属、白酒板块跌幅居前。 盘面上，创新药概念再度爆发，舒泰神（300204）、常山药业（300255）、海辰药业（300584）、睿智医药（300149）、联化科技 （002250）、众生药业（002317）等多股涨停。足球概念持续活跃，共创草坪（605099）6连板，金陵体育（300651）涨超10%。互 联网金融板块走强，南华期货（603093）、恒宝股份（002104）涨停。核电股午后活跃，百利电气（600468）、哈焊华通 （301137）、合锻智能（603011）涨停。贵金属板块领跌，赤峰黄金（600988）、山东黄金（600547）跌幅居前。 暗盘资金一眼洞悉庄家意图>> 涨停天梯榜： 【6连板】 共创草坪。 【5连板】 金时科技（002951）。 【4连板】 中嘉博创（000889）、易明医药（0 ...

Group 1 - The A-share market's innovative drug concept stocks have shown strong performance, with the innovative drug sector index reaching a historical high [1] - Notable individual stock performances include Xinghao Pharmaceutical rising over 25%, RuiZhi Pharmaceutical hitting a 20% limit up, and Changshan Pharmaceutical reaching a historical high [1][2] - The overall pharmaceutical sector has experienced a prolonged adjustment period, resulting in low valuations and underweight public holdings, indicating potential for recovery and structural opportunities [2] Group 2 - Specific stock performances include: - Xinghao Pharmaceutical: 25.82% increase, market cap of 3.045 billion [2] - RuiZhi Pharmaceutical: 19.98% increase, market cap of 5.801 billion [2] - Changshan Pharmaceutical: 19.97% increase, market cap of 47.9 billion [2] - Shutaishen: 12.12% increase, market cap of 15.6 billion [2] - The report from China Galaxy Securities suggests that the pharmaceutical market is expected to see continuous recovery and that innovative drug companies will benefit from policy support and improved payment conditions by 2025 [2]

Core Viewpoint - Changshan Pharmaceutical's stock price has surged nearly 200% over the past two months, reaching a historical high, despite the company's operational challenges and reliance on heparin products [1][3]. Company Performance - In 2024, Changshan Pharmaceutical reported a revenue of 1.031 billion yuan, a year-on-year decline of 26.92%, while the net profit attributable to shareholders was -249 million yuan, reflecting a 79.88% reduction in losses [4]. - The company's revenue is heavily dependent on heparin products, which account for nearly 87% of total income, indicating a lack of diversification in its product portfolio [4]. Product Development - The company is in the process of registering its innovative drug, Aibennate Injection, which is a GLP-1 receptor agonist for treating type 2 diabetes, but it is not the first of its kind in the industry [3]. - Aibennate Injection is currently in the registration phase and has not yet been launched for sale. The company faces significant market competition risks even if the product is approved [3]. - The clinical trial application for Aibennate Injection for weight loss indications has been accepted by the National Medical Products Administration, but there is uncertainty regarding the approval and subsequent trial outcomes [3].

医药医疗股持续走强，创新药方向领涨，常山药业触及20cm涨停，股价再创历史新高，睿智医药、海 辰药业、罗欣药业、昂利康、众生药业、联化科技等多股封板。 ...

Market Overview - On June 6, the Shanghai Composite Index rose by 0.04%, while the Shenzhen Component Index fell by 0.19%, and the ChiNext Index decreased by 0.45% [2] - A total of 54 stocks appeared on the daily trading list due to unusual trading activity, with the highest net inflow of funds into China Electric Power Xinlong (002298.SZ) amounting to 236 million yuan [2] Stock Performance - China Electric Power Xinlong saw a closing price increase of 9.96% with a turnover rate of 19.42%, while Snowman Co., Ltd. (002639.SZ) experienced a net outflow of 210 million yuan and closed down by 1.23% with a turnover rate of 46.27% [2] - Among the 54 stocks, 34 were net bought, and 20 were net sold, indicating a general preference for buying [2] Institutional Activity - On June 6, 26 stocks on the trading list had institutional participation, with a total net purchase of 439 million yuan, where institutions net bought 16 stocks and net sold 10 stocks [2] - The stock with the highest institutional net purchase was Xiongdi Technology (300546.SZ), which closed down by 10.56% with a turnover rate of 47.82% [3] Northbound Capital - Northbound capital participated in 16 stocks on the trading list, with a total net purchase of 304 million yuan, including a net purchase of 54.65 million yuan from the Shanghai Stock Connect and 249 million yuan from the Shenzhen Stock Connect [6] - The stock with the highest net purchase from northbound capital was Changshan Pharmaceutical (300255.SZ), amounting to 202 million yuan, while Snowman Co., Ltd. had the highest net sell of 107 million yuan [6] Common Trends - Both institutions and northbound capital collectively net bought stocks such as Changshan Pharmaceutical, Hailian Jinhui, Hengbao Co., Ltd., Haoshanghao, Maiwei Biotechnology, and Hunan Development [7] - There was a divergence in the trading of Cambridge Technology (603083.SH) and Zhongchong Co., Ltd., with institutions net buying Zhongchong Co., Ltd. while northbound capital net sold it [7]